Are Analysts Bearish SkyePharma PLC (LON:SKP) After Last Week?

Out of 1 analysts covering SkyePharma PLC (LON:SKP), 1 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. SkyePharma PLC was the topic in 22 analyst reports since July 30, 2015 according to StockzIntelligence Inc. Below is a list of SkyePharma PLC (LON:SKP) latest ratings and price target changes.

17/02/2016 Broker: Stifel Nicolaus Rating: Buy Old Target: GBX 460.00 New Target: GBX 460.00 Maintain
28/01/2016 Broker: Stifel Nicolaus Rating: Buy Old Target: GBX 460.00 New Target: GBX 460.00 Maintain
28/01/2016 Broker: N+1 Singer Rating: Corporate Maintain
22/01/2016 Broker: FinnCap Rating: Buy Maintain
11/01/2016 Broker: Stifel Nicolaus Rating: Buy Old Target: GBX 460.00 New Target: GBX 460.00 Maintain
11/01/2016 Broker: N+1 Singer Rating: Corporate Maintain
11/01/2016 Broker: FinnCap Rating: Under Review Under Review
08/01/2016 Broker: Stifel Nicolaus Rating: Buy Old Target: GBX 460.00 New Target: GBX 460.00 Maintain
08/01/2016 Broker: N+1 Singer Rating: Corporate Maintain
23/12/2015 Broker: N+1 Singer Rating: Corporate Maintain

The stock increased 0.84% or GBX 3.25 on February 26, hitting GBX 389.25. About 12,665 shares traded hands. SkyePharma PLC (LON:SKP) has risen 39.52% since July 28, 2015 and is uptrending. It has outperformed by 47.20% the S&P500.

Skyepharma PLC is a specialty pharmaceutical company. The company has a market cap of 414.42 million GBP. The Firm is engaged in the development and delivery of oral and inhalation pharmaceutical products. It has 25.24 P/E ratio. The Company’s products pipeline includes four inhalation products, 10 oral products, one topical product and one injectable product.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Add Comment